Laboratory values on admission, after the first dose of tocilizumab and at the time of hospital discharge
| Laboratory tests | |||||
| Inflammatory markers | Reference values | On admission | Tocilizumab dose #1 (day 9) | Tocilizumab dose #2 (day 16) | On hospital discharge (day 27) |
| Ferritin (ng/mL) | 28–365 | >40,000 | 20,254 | 10,562 | 4565 |
| LDH (U/L) | 87–241 | 3465 | 1515 | 1079 | 750 |
| ESR (mm/h) | 0–16 | 85 | 30 | 2 | NA |
| CRP (mg/L) | 0–3 | 281 | 38.1 | <2.90 | <4.00 |
| sIL-2R (U/mL) | ≤1033 | 23,020 | NA | NA | 7236 |
| IL-6 (pg/mL) | ≤5 | 75 | NA | NA | NA |
| Liver function tests | |||||
| AST (U/L) | 3–34 | 536 | 119 | 120 | 75 |
| ALT (U/L) | 15–41 | 384 | 151 | 132 | 141 |
| ALP (IU/L) | 45–117 | 819 | 801 | 627 | 613 |
| Blood count | |||||
| WBC (x10∧9/L) | 4000–10,800 | 2200 | 9600 | 12,800 | 5300 |
| ANC (x10∧9/L) | >1500 | 658 | 7000 | 11,100 | 3063 |
| ALC (x10∧9/L) | 600–4900 | 579 | 600 | 700 | 1000 |
| Hemoglobin (g/L) | 125-165 | 114 | 69 | 70 | 82 |
| Platelet count (x10∧9/L) | 145–400 | 191 | 254 | 113 | 119 |
| Basic metabolic panel | |||||
| Creatinine (mg/dL) | 0.66–1.50 | 1.9 | 8.4 | 3.4 | 1.1 |
ALC, absolute lymphocyte count; ALP, alkaline phosphatase; ALT, alanine serum aminotransferase; ANC, absolute neutrophil count; AST, aspartate serum aminotransferase; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; sIL-2R, soluble IL-2 receptor; WBC, white blood cell.